(2) All share-based compensation was excluded for the non-GAAP analysis.
(3) Represents a reclaiming of paid French Withholding Tax of $550 thousand for the $11 million upfront payment from Servier.
(4) Represents the therapeutic discovery project tax grant, net of related expenses.
(5) Represents the pro-rata portion of services performed under the Servier Collaboration arrangement prior to fiscal year 2010.Reconciliation of Selected GAAP Measures to Non-GAAP Measures (1)(unaudited; in thousands, except per share data)Six Months EndedDecember 31,20102009GAAP net loss$
(5,063)Adjustments:Research & development share-based compensation(2)
2,961374General & administrative share-based compensation(2)
1,149446Interest adjustment for related party loan(3)
-21Income tax adjustment(4)
-(550)Therapeutic discovery project tax grant, net(5)
(586)-3,524291License and collaboration revenues(6)
-(1,211)-(1,211)Non-GAAP net loss$
(5,983)Non-GAAP net loss per share$
(0.13)(1) This presentation includes non-GAAP measures. Our non-GAAP measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our financial statements prepared in accordance with GAAP.(2) All share-based compensation was excluded for the non-GAAP analysis.(3) Due to the below market interest rate of the related party loan, total GAAP interest expense includes non-cash interest expense of $21 for the six months ended December 31, 2009.(4) Represents a recla
|SOURCE Pharmacyclics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved